Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
30160364
DOI
10.1002/pbc.27431
Knihovny.cz E-zdroje
- Klíčová slova
- Ph+ leukemia, generic medication, imatinib inhibitor, pediatric, tyrosine kinase,
- MeSH
- chronická myeloidní leukemie farmakoterapie MeSH
- dítě MeSH
- generika terapeutické užití MeSH
- imatinib mesylát terapeutické užití MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- lidé MeSH
- protinádorové látky terapeutické užití MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- generika MeSH
- imatinib mesylát MeSH
- inhibitory proteinkinas MeSH
- protinádorové látky MeSH
Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome-positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.
Department of Pediatric Hematology Uludağ University Hospital Görükle Bursa Turkey
Department of Pediatrics Keio University School of Medicine Tokyo Japan
Department of Pediatrics Tettamanti Research Center University of Milano Bicocca Monza Italy
Pediatric Hematology Immunology Department Paris Diderot University Paris France
Pediatric Hematology Immunology Department University Hospital Robert Debré Paris France
Citace poskytuje Crossref.org
